O 304

Drug Profile

O 304

Alternative Names: O304

Latest Information Update: 24 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Betagenon
  • Class Antihyperglycaemics; Antineoplastics; Benzamides; Cardiovascular therapies; Obesity therapies; Small molecules; Thiadiazoles
  • Mechanism of Action AMP activated protein kinase stimulants; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Metabolic disorders; Peripheral arterial disorders; Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I Metabolic disorders; Peripheral arterial disorders
  • Preclinical Cancer

Most Recent Events

  • 18 May 2018 Efficacy data from a phase I and the phase IIa TELLUS trial in Type-2 diabetes mellitus released by Betagenon
  • 02 Nov 2017 Adverse events and efficacy data from a phase II trial in Type II diabetes mellitus released by Betagenon
  • 09 Aug 2017 Betagenon completes the phase II TELLUS trial in Type-2 diabetes mellitus in Sweden (PO) (EudraCT2016-002183-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top